sorafenib has been researched along with Local Neoplasm Recurrence in 225 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (7.11) | 29.6817 |
| 2010's | 147 (65.33) | 24.3611 |
| 2020's | 62 (27.56) | 2.80 |
| Authors | Studies |
|---|---|
| Antonelli, A; Benvenga, S; Elia, G; Fallahi, P; Ferrari, SM; Mazzi, V; Paparo, SR; Ragusa, F; Ulisse, S | 1 |
| Araki, A; Asayama, I; Kanasaki, K; Makino, H; Miyake, H; Morita, M; Nakao, M; Notsu, M; Otani, H; Uchino, S; Yamamoto, M; Yamauchi, M | 1 |
| Chu, T; Hu, M; Li, B; Li, S; Liu, R; Lu, Z; Meng, H; Nie, G; Qi, F; Qie, Y; Wei, J; Wu, S; Wu, Z; Xu, S; Yang, Z; Zhang, X; Zhao, G; Zhao, Y | 1 |
| Cao, W; Cui, C; Feng, W; Pi, X | 1 |
| Li, R; Li, S; Li, Y; Liang, P; Mao, X; Wang, C; Wang, J; Wang, X; Xie, X; Zhou, Q | 1 |
| Cole, BL; Leary, SES; Lockwood, CM; Starr, K | 1 |
| De Giorgio, M; Di Costanzo, GG; Di Donato, MF; Fagiuoli, S; Giuffrida, P; Granito, A; Iavarone, M; Ielasi, L; Pallotta, DP; Piscaglia, F; Pressiani, T; Sacco, R; Sansone, V; Tovoli, F; Trevisani, F | 1 |
| Chen, J; Jin, Z; Li, H; Xiong, Z; Zhang, B; Zhang, S; Zheng, Y; Zhu, X | 1 |
| Hou, Y; Hu, W; Tan, K; Wang, Y; Yang, G | 1 |
| Choi, KH; Kim, CW; Kim, SM; Kim, SY; Lee, JH; Lim, JH; Pan, CH; Park, K; Park, KC; Weicker, R; Yun, HJ | 1 |
| Battiston, C; Citterio, D; Droz Dit Busset, M; Flores, M; Mazzaferro, V; Sposito, C; Virdis, M | 1 |
| Hu, J; Jiang, X; Peng, W; Zhang, L; Zhang, W; Zhang, Y | 1 |
| Abu Hilal, M; Aldrighetti, L; Antonucci, A; Ardito, F; Baiocchi, GL; Bernasconi, DP; Chiarelli, M; Cipriani, F; Conci, S; Dalla Valle, R; Delvecchio, A; Dominioni, T; Donadon, M; Ercolani, G; Famularo, S; Farinati, F; Fazio, F; Ferrari, C; Ferrero, A; Frena, A; Fumagalli, L; Germani, P; Giuliante, F; Grazi, GL; Griseri, G; Hasegawa, K; Iaria, M; Jovine, E; Kawaguchi, Y; La Barba, G; Lai, Q; Maestri, M; Memeo, R; Molfino, S; Patauner, S; Perri, P; Pinotti, E; Piscaglia, F; Romano, F; Romano, M; Rossi, M; Ruzzenente, A; Tarchi, P; Torzilli, G; Valsecchi, MG; Zago, M; Zanello, M; Zanus, G; Zimmitti, G | 1 |
| Chen, S; Feng, R; Hu, Y; Li, J; Li, M; Li, X; Li, Z; Liao, X; Mo, S; Qian, W; Tang, M; Xie, C; Xu, Y; Yu, R; Yuan, S; Zhang, S | 1 |
| Arakawa, A; Iwata, S; Kawai, A; Kobayashi, E; Kumamoto, T; Maniwa, J; Nakajima, M; Ogawa, C; Shirakawa, N; Sugiyama, M; Tanimura, K; Tao, K; Watanabe, Y; Yoneda, A | 1 |
| Bu, H; Chen, M; Chen, Y; Shao, M; Shen, J; Shi, Y; Shu, Y; Tao, Q; Wen, T; Wu, Z; Xu, Q; Xu, Y; Yang, J; Zhou, Y | 1 |
| Farinati, F; Pelizzaro, F; Pinto, E; Russo, FP | 1 |
| Chen, Y; Chi, P; Deng, L; Fan, Z; Huang, F; Huang, X; Jiang, L; Li, X; Liang, X; Lin, R; Liu, H; Liu, Q; Luo, X; Shao, R; Shi, P; Sun, J; Tu, S; Wang, Y; Wang, Z; Xu, N; Xu, Y; Xuan, L; Yang, K; Zhang, Y | 1 |
| Airoldi, A; Antonelli, B; Cesarini, L; Donato, MF; Iavarone, M; Invernizzi, F; Lampertico, P; Maggi, U; Manini, MA; Mazza, S; Rossi, G; Sangiovanni, A; Saverio Belli, L; Zavaglia, C | 1 |
| Au, CH; Chan, TL; Ip, HW; Kwong, YL; Lam, SSY; Lau, JSM; Lee, HKK; Leung, AYH; Leung, GMK; Li, W; Luk, TH; Ma, ESK; Ng, NKL; Tsui, SP; Yang, N; Yip, SF; Zhang, C | 1 |
| DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jegede, OA; Jewett, MAS; Kane, CJ; Lee, Z; Manola, J; Messing, EM; Pins, MR; Uzzo, RG; Wood, CG | 1 |
| Cui, YL; Ding, CH; Ding, J; Feng, JF; Huang, CK; Liu, JP; Lu, B; Xie, WF; Xu, WP; Yang, Y; Zhang, X; Zhou, WP; Zhu, CP | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Cheng, Q; Gao, J; Li, Z; Wang, Y; Xiang, X; Zheng, SM; Zhu, J | 1 |
| De la Cruz Lombardo, J; González Grande, R; Jiménez Pérez, M; López Ortega, S; Santaella Leiva, I | 1 |
| Cai, SH; Cho, WCS; Lau, EYT; Lee, TKW; Lei, MML; Leung, CON; Leung, HW; Ma, S; Ma, VWS; Mok, EHK; Ng, IOL; Yu, HJ; Yun, JP | 1 |
| Arai, K; Asahina, Y; Hashiba, T; Hayashi, T; Honda, M; Iida, N; Kaneko, S; Kawaguchi, K; Mizukoshi, E; Nio, K; Ohta, T; Okada, H; Sakai, Y; Shimakami, T; Takamura, H; Takatori, H; Terashima, T; Yamashita, T | 1 |
| Ba, Q; Gao, Z; Li, J; Li, X; Qiu, L; Sun, M; Wang, F; Wang, H; Wang, W; Yang, C; Yang, Y; Yao, W; You, R | 1 |
| Kumar, A | 1 |
| Goto, W; Hamano, G; Kanazawa, A; Kikuchi, T; Kinoshita, M; Kodai, S; Maeda, K; Miura, K; Murata, A; Nishio, K; Nobori, C; Shimizu, S; Shirai, D; Tashima, T; Yonemitsu, K | 1 |
| Chang, WT; Chen, LA; Chuang, SC; Huang, JW; Kuo, KK; Lee, KT; Lin, CS; Su, WL; Wang, SN; Wang, YC | 1 |
| Nakamura, T; Sakamoto, K; Takada, Y; Tamura, K; Tohyama, T; Wakisaka, H; Watanabe, J | 1 |
| Abou-Alfa, GK; El Dika, I; Makki, I | 1 |
| Gao, ZQ; Li, DY; Shen, PC; Tang, Z | 1 |
| Endo, M; Fukuda, K; Hasegawa, N; Hattori, J; Hirose, S; Hyodo, I; Ishige, K; Komatsu, Y; Mizui, T; Nagase, M; Sato, M; Yamaura, M | 1 |
| Ardelt, MA; Arnold, GJ; Fröhlich, T; Gerbes, AL; Huber-Cantonati, P; Kiemer, AK; Koeberle, A; Koenig, LM; Meßner, M; Müller, M; Ortler, C; Pachmayr, J; Pein, H; Rothenfußer, S; Schmitt, S; Vollmar, AM; Zischka, H; Zobel, L | 1 |
| Mancuso, A | 1 |
| Iavarone, M; Invernizzi, F | 1 |
| An, D; Annunziata, CM; Cao, L; Chen, H; Choyke, P; Hays, JL; Kohn, EC; Lee, JM; Minasian, LM; Steinberg, SM; Turkbey, IB; Wright, J; Yu, M | 1 |
| Gu, W; Tong, Z | 1 |
| Isik, B; Sarici, B; Yilmaz, S | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Bitzer, M; Denzlinger, C; Gellert, K; Ghadimi, M; Hinke, A; Hofheinz, R; Lammert, F; Liersch, T; Lindig, U; Maschmeyer, G; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Stübs, P; Waldschmidt, D | 1 |
| Card, PB; Knox, JJ; Lim, H; Liu, D; Meyers, BM; Ramjeesingh, R; Tam, VC | 1 |
| Feng, Y; Fu, Y; Guo, G; Guo, W; Hou, H; Huang, C; Jiang, C; Kuang, Y; Li, H; Li, X; Mu, M; Tong, A; Wang, J; Wang, Y; Wang, Z; Xu, J; Yang, C; Yang, H; Zhang, Z; Zhao, S; Zhou, L | 1 |
| Arai, M; Hanai, A; Kawaguchi, T; Mashiko, T; Miyaji, T; Morizane, C; Oshiba, F; Ryu, A; Shimizu, Y; Takagi, Y; Takashima, A; Uchitomi, Y; Yamaguchi, T; Yamazaki, N; Zenda, S | 1 |
| Abe, Y; Eguchi, H; Hayashi, Y; Hikita, H; Kodama, T; Maesaka, K; Mita, E; Motooka, D; Myojin, Y; Ohkawa, K; Sakamori, R; Sato, Y; Taguchi, A; Takehara, T; Tanaka, S; Tatsumi, T | 1 |
| Atzori, F; Bearz, A; Cappelletti, V; Chiuri, VE; Claps, M; Cognetti, F; de Braud, FG; Donini, M; Guadalupi, V; Mennitto, A; Miceli, R; Milella, M; Morelli, F; Mosca, A; Ortega, C; Procopio, G; Sepe, P; Verzoni, E | 1 |
| Haruna, Y; Kawamoto, S; Yakushijin, T | 1 |
| Cheng, W; Gong, YF; Guan, XY; Kong, FE; Li, GM; Li, HL; Li, MM; Liu, M; Loong, JHC; Ma, NF; Ma, S; Mo, JQ; Tang, H; Tang, YQ; Xi, SY; Xie, MB; Zhang, Y; Zhao, Y; Zhu, WJ | 1 |
| Adachi, Y; Endo, T; Hata, F; Ikeda, K; Ishii, Y; Iwata, N; Kato, Y; Kikuchi, T; Makiguchi, Y; Minami, T; Mita, H; Yoshida, Y | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hanoun, M; Herbst, R; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Meinhardt, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Platzbecker, U; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M | 1 |
| Cheng, Q; Gao, J; Li, Z; Wang, Y; Xiang, X; Zheng, S; Zhu, J | 1 |
| Adam, R; Baba, H; Cherqui, D; Coilly, A; De Martin, E; El-Domiaty, N; Karam, V; Maria Antonini, T; Nitta, H; Rosmorduc, O; Saliba, F; Samuel, D; Sobesky, R; Vibert, E; Younès, A | 1 |
| Atkins, MB; Escudier, BJ; Hutson, TE; McDermott, DF; Needle, MN; Pal, SK; Rini, BI; Szarek, M | 1 |
| Chan, A; Cheung, TT; Chiu, J; Kwok, GGW; Leung, R; Li, BCW; Lo, CM; Ma, KW; She, WH; Shing, K; Tang, V; Tsang, J; Yau, T | 1 |
| Huang, S; Li, D; Sun, L; Wu, J; Zhuang, L | 1 |
| Gao, J; Jing, Z; Li, J; Liu, F; Nan, P; Niu, F; Sun, Y; Tian, L; Xie, X; Zhao, X; Zhao, Y; Zhou, L; Zhu, Y | 1 |
| Bridle, KR; Cao, L; Crawford, DHG; Jayachandran, A; Shrestha, R | 1 |
| Al-Jahdhami, S; Burney, IA; Kakaria, AK | 1 |
| Amiri-Kordestani, L; Beaver, JA; Bhatnagar, V; Chang, E; Chen, XH; Fiero, MH; Fourie Zirkelbach, J; Goldberg, KB; Ibrahim, A; Kluetz, PG; Pazdur, R; Qiu, J; Ricks, TK; Tang, S; Weinstock, C; Yu, J; Zahalka, E; Zhang, L; Zhao, M | 1 |
| Babajanyan, S; Bruenderman, E; Cohn, A; Foreman, P; Geschwind, JF; Gholam, P; Goldenberg, A; Mantry, P; Martin, RC; McGuire, B; Miksad, R; Piperdi, B; Sanyal, A; Zigmont, E | 1 |
| Karasawa, Y; Kawamura, S; Kojima, K; Kondo, M; Maeshima, S; Ohki, T; Seki, M; Shioda, Y; Tagawa, K; Toda, N | 1 |
| Mancuso, A; Maringhini, A | 1 |
| Benech, N; Saurin, JC; Walter, T | 1 |
| Huang, X; Li, G; Li, W; Mu, X; Qian, X; Qin, J; Sun, B; Tan, S; Tan, Z; Wang, X; Xu, X; Zhang, W; Zhu, Z | 1 |
| Ballarin, R; Berretta, M; Di Benedetto, F; Guerrini, GP; Magistri, P; Pecchi, A; Tarantino, G | 1 |
| Barbera, MA; Brandi, G; Cescon, M; Cucchetti, A; De Lorenzo, S; De Pace, V; Del Gaudio, M; Frega, G; Maroni, L; Neri, F; Palloni, A; Pantaleo, MA; Pinna, AD; Ravaioli, M; Ripoli, MC | 1 |
| Bersanelli, M; Buti, S; DiPaola, RS; Haas, NB; Manola, J; Puligandla, M; Taguchi, S | 1 |
| Abrey, LE; Aldape, K; Chang, S; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Ebiana, VA; Gilbert, M; Kuhn, J; Levin, VA; Lieberman, F; Mehta, MP; Nghiemphu, PL; Prados, M; Robins, HI; Wen, P; Wright, JJ; Yung, WKA | 1 |
| Deguchi, A; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, M; Ishikawa, T; Joko, K; Koizumi, Y; Kudo, M; Kumada, T; Michitaka, K; Ochi, H; Shimada, N; Tada, T; Tajiri, K; Toyoda, H; Tsuji, K | 1 |
| Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS | 1 |
| Anderson, SK; Buckner, JC; Dancey, J; Erickson, BJ; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaluza, V; Sarkaria, JN; Schiff, D; Schwerkoske, JF; Stella, P; Twohy, E; Wright, J | 1 |
| Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X | 1 |
| Eucker, J; Gomez-Roca, C; Graudenz, K; Huang, F; Lettieri, J; Marmé, F; Peña, C; Trnkova, ZJ | 1 |
| Deng, L; Fan, Z; Han, M; Huang, F; Huang, X; Jiang, E; Liang, X; Lin, R; Liu, Q; Sun, J; Wang, Y; Wu, B; Xu, N; Xuan, L; Ye, J; Yin, C; Zhang, Y | 1 |
| Das, K; Eason, JD; Helmick, RA; Kocak, M; Nair, SP; Satapathy, SK; Vanatta, JM | 1 |
| Ahn, CS; Ha, TY; Hwang, S; Jung, DH; Jwa, EK; Kim, KH; Kim, N; Kwon, JH; Lee, KJ; Lee, SG; Moon, DB; Park, GC; Ryoo, BY; Song, GW; Tak, E | 1 |
| Zhang, HM; Zheng, H; Zheng, WP | 1 |
| Bruix, J; Sanduzzi-Zamparelli, M | 1 |
| Corrado, G; Ferrandina, G | 1 |
| Bassaganyas, L; Bruix, J; Camps, J; Chau, GY; Cillo, U; Croitoru, AE; de la Mata, M; Gane, E; Kokudo, N; Lee, HC; Llovet, JM; Lupo, L; Mazzaferro, V; Meinhardt, G; Moeini, A; Montal, R; Park, JW; Pena, C; Pinyol, R; Roayaie, S; Rodriguez-Carunchio, L; Sia, D; Solé, M; Strasser, S; Takayama, T; Thung, SN; Torrecilla, S; Verslype, C; Villanueva, A; Zhang, Z | 1 |
| DiPaola, RS; Haas, NB; Narayan, V; Puligandla, M; Subramanian, P; Uzzo, R | 1 |
| Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Gavalas, N; Gkerzelis, I; Karavasilis, V; Kostouros, E; Koutras, A; Koutsoukos, K; Samantas, E; Tzannis, K; Zagouri, F | 1 |
| Cho, EJ; Cho, H; Kang, SH; Kim, YJ; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ | 1 |
| Kim, BH; Park, JW | 1 |
| Kim, DY; Kim, YJ; Lee, SJ; Lim, HY; Lim, TS; Park, JW; Ryoo, BY; Yoo, C; Yu, SJ | 1 |
| Chen, F; Chen, P; He, D; Lu, J; Wang, H; Wang, Y; Wang, Z; Wei, D; Wu, G; Ye, Y; Yuan, J; Zheng, Y; Zhu, Z | 1 |
| Arcese, W; Battipaglia, G; Bazarbachi, A; Blaise, D; Chantepie, S; Chevallier, P; Cornelissen, JJ; Djabali, A; El Cheikh, J; Esteve, J; Forcade, E; Hashaishi, K; Labopin, M; Medinger, M; Mohty, M; Nagler, A; Orvain, C; Passweg, J; Socié, G | 1 |
| Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A | 1 |
| Chen, M; Chen, S; Chen, Z; Feng, S; Kuang, M; Li, J; Mei, J; Peng, S; Peng, Z; Qian, G; Wang, Y; Xiao, H; Zhou, Q | 1 |
| Celine, J; Couvreur, K; Frederic, D; Marlies, B; Philippe, D; Randal, D; Sylvie, R | 1 |
| Ankoma-Sey, V; Balogh, J; Boktour, M; Divatia, MK; Duchini, A; Egwim, C; Gaber, AO; Galati, J; Ghobrial, RM; Graviss, EA; Heyne, K; Lunsford, K; McFadden, R; Mobley, C; Monsour, HP; Nguyen, DT; Saharia, A; Victor, DW | 1 |
| Bu, Y; Chang, F; Jia, F; Jia, Q; Jiang, S; Liao, X; Ning, P; Song, G; Xiao, X; Zhang, M | 1 |
| Amaddeo, G; Anders, M; Bhoori, S; Bruix, J; Crespo, G; Cristóbal, MR; Czauderna, C; Donato, MF; Giorgio, M; González-Diéguez, ML; Iavarone, M; Invernizzi, F; Lampertico, P; López, MF; Manini, MA; Mazzaferro, V; Piñero, F; Pinter, M; Regnault, H; Reig, M; Rodríguez, MJB; Sanduzzi-Zamparelli, M; Soteras, GA; Varela, M; Villadsen, GE; Weinmann, A; Wörns, MA | 1 |
| Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| Dai, Z; Fan, J; Gu, F; Huang, X; Jiang, J; Tan, C; Wang, Z; Xu, M; Yan, J; Zhou, J | 1 |
| Hui, KM; Ooi, LL; Xia, H | 1 |
| Bhoori, S; Bongini, M; Flores Reyes, M; Germini, A; Grossi, G; Mariani, L; Mazzaferro, V; Sposito, C | 1 |
| Majno, P; Mentha, G; Toso, C | 1 |
| Alattar, ML; Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Dellasala, S; Faderl, S; Garcia-Manero, G; Grunwald, MR; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Pierce, S; Rajkhowa, T; Ravandi, F; Richie, MA; Rudek, MA | 1 |
| Carithers, R; Halldorson, J; Jia, N; Lin, EH; Liou, I; Perkins, J; Rao, S; Reyes, J; Stohr, E; Yeh, M | 1 |
| Cao, D; Chen, C; Chen, SZ; Ding, J; Feng, GS; Han, T; Huang, L; Sun, W; Tang, L; Wang, HY; Wang, X; Wen, W; Wu, MC; Xiang, DM | 1 |
| Gascoyne, RD; Go, RS; Greenwald, DR; Horning, S; Kahl, BS; King, D; Kolesar, J; Li, H; Luger, SM; Patel, T | 1 |
| Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH | 1 |
| Moroni, M; Zanlorenzi, L | 1 |
| Ichiyanagi, N; Kamata, S; Yoshinaga, A | 1 |
| Ganten, TM; Hoffmann, K; Koschny, R; Mehrabi, A; Pfeiffenberger, J; Radeleff, B; Schemmer, P; Schmitz, A; Stremmel, W | 1 |
| Baba, T; Konishi, I; Koshiyama, M; Matsumura, N; Yamaguchi, K; Yoshioka, Y | 1 |
| Azzarà, A; Benedetti, E; Buda, G; Caracciolo, F; Carulli, G; Fontanelli, G; Galimberti, S; Orciuolo, E; Petrini, M; Rocco, M | 1 |
| Dent, P | 1 |
| Chen, K; Janssen, HL; Man, K; Metselaar, HJ; Pan, Q; Peppelenbosch, MP | 1 |
| Ackerl, M; Dieckmann, K; Flechl, B; Hainfellner, J; Hassler, MR; Marosi, C; Preusser, M; Sax, C; Widhalm, G; Wöhrer, A | 1 |
| Behnke, M; Bornstein, K; Cotterell, A; Fisher, RA; Fulcher, A; Lee, DD; Posner, MP; Ramanathan, R; Sharma, A; Stravitz, RT; Sydnor, M | 1 |
| Bruix, J; Gores, GJ; Mazzaferro, V | 1 |
| Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ | 1 |
| Chen, L; Li, M; Liu, M; Ruan, M; Shen, Y | 1 |
| Belli, LS; Mancuso, A; Mazzarelli, C; Perricone, G; Zavaglia, C | 1 |
| Burra, P; Castelli, G; Cillo, U; Farinati, F; Giacomin, A; Senzolo, M; Vitale, A | 1 |
| Bambury, RM; Morris, PG | 1 |
| Barbarotta, L; Cooper, D; Foss, F; Gibson, JF; Irizarry, D; Lansigan, F; Seropian, S | 1 |
| Barlogie, B; Hoering, A; Hussein, MA; Mazzoni, S; Orlowski, RZ; Popplewell, LL; Sexton, R; Srkalovic, G; Trivedi, H; Zonder, JA | 1 |
| Alsina, AE; Arrobas, J; Franco, E; Kemmer, N; Makris, A; Nenos, V; Sucre, E | 1 |
| Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E | 1 |
| Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M | 1 |
| Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL | 1 |
| Bie, P; Huan, HB; Lau, WY; Ma, KS; Xia, F | 1 |
| Chen, WT; Jeng, WJ; Lin, CC; Lin, CY; Lin, SM; Sheen, IS | 1 |
| Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Senda, S; Shimizu, S; Takahashi, H | 1 |
| Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G | 2 |
| Belli, L; Cabibbo, G; Cammà, C; Enea, M; Galvano, A; Mancuso, A; Mazzola, A; Perricone, G; Zavaglia, C | 1 |
| Bi, F; Hao, P; Li, J; Li, Q; Wen, F; Xia, F; Yan, W; Yang, Y; Zhang, P | 1 |
| Han, M; Jing, Y; Kan, X; Liu, KH; Pan, JC; Wan, QY; Wang, Q; Yang, Y; Zhu, M | 1 |
| Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J | 1 |
| Cho, M; Choi, CW; Heo, J; Hong, YM; Kang, DH; Kim, HW; Lim, W; Park, SB; Woo, HY; Yoon, KT | 1 |
| Bornhäuser, M; Brendel, C; Burchert, A; Charles, J; Ellenrieder, V; Gattenlöhner, S; Hessmann, E; Inselmann, S; Metzelder, SK; Michel, C; Neubauer, A; Rehberger, M; Sohlbach, K; Solovey, M; Stiewe, T; Ten Haaf, A; von Bonin, M; Wang, Y | 1 |
| Kim, JK; Seo, MS; Shim, JY | 1 |
| Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C | 1 |
| Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J | 1 |
| Wirth, LJ | 1 |
| Kanda, M; Kodera, Y; Sugimoto, H | 1 |
| Ekser, B; Fridell, JA; Klingler, KR; Kubal, CA; Maluccio, MA; Mangus, RS; Nagai, S; Tector, AJ | 1 |
| Azoulay, D; Carra, MC; de'Angelis, N; Landi, F | 1 |
| Cai, J; Ye, X; Zhu, Y | 1 |
| Park, JG | 1 |
| Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T | 1 |
| Duprez, T; Filleul, B; Laruelle, M; Machiels, JP | 1 |
| Bayhan, T; Cetin, M; Gumruk, F; Isgandarova, F; Kuskonmaz, B; Tavil, B; Unal, S | 1 |
| Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B | 1 |
| Beck, JF; Ernst, J; Ernst, T; Gruhn, B; Rinke, J; Schäfer, V; Wittig, S | 1 |
| Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J | 1 |
| Cai, XB; Hou, Y; Li, J; Liu, B | 1 |
| Guo, X; Han, G; Li, H; Qi, X; Zhao, Y | 1 |
| Arai, K; Honda, M; Horii, R; Kaneko, S; Kawaguchi, K; Kitamura, K; Mizukoshi, E; Sakai, Y; Terashima, T; Yamashita, T | 1 |
| Bie, P; Huan, HB; Lau, WY; Li, XW; Ma, KS; Wen, XD; Wu, LL; Xia, F | 1 |
| Hong, TH; Kim, DG; Na, GH; You, YK | 1 |
| Jia, HL; Qin, LX | 1 |
| Azoulay, D; Calderaro, J; Compagnon, P; Costentin, C; de'Angelis, N; Feray, C; Lahat, E; Landi, F; Lim, C; Luciani, A; Nencioni, M; Palen, A; Salloum, C | 1 |
| Castinetti, F; Eroukhmanoff, J; Penel, N; Salas, S | 1 |
| Li, J; Shen, F; Wan, X; Wang, K; Wu, D; Xia, Y; Yan, Z; Yang, P; Zhai, X | 1 |
| Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G | 1 |
| Bouattour, M; de Gramont, A; Faivre, S; Soubrane, O | 1 |
| Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
| Harada, N; Harimoto, N; Ikegami, T; Itoh, S; Kawasaki, J; Maehara, Y; Motomura, T; Nagatsu, A; Soejima, Y; Uchiyama, H; Yoshizumi, T | 1 |
| Heinemann, V; Stemmler, HJ | 1 |
| Bierer, S; Bolenz, C; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C | 1 |
| Bex, A; Cosentino, M; Ficarra, V; Flörcken, A; Grünwald, V; Johannsen, M; Kloeters, C; Miller, K; Rief, M; Rogalla, P; Roigas, J | 1 |
| Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM | 1 |
| Ye, SL | 1 |
| Antonescu, CR; Blachère, NE; Brockstein, B; Cooney, MM; D'Adamo, DR; Edgar, MA; Elias, AD; Hensley, ML; Keohan, ML; Kraft, AS; Livingston, MB; Maki, RG; Mita, MM; Qin, LX; Saulle, M; Schuetze, SM; Schwartz, GK; Schwartz, LH; Takimoto, CH; Undevia, SD | 1 |
| Mendizabal, M; Reddy, KR | 1 |
| Blumenschein, GR; Cihon, F; Cupit, L; Fossella, F; Gatzemeier, U; O'Leary, J; Reck, M; Stewart, DJ | 1 |
| Printz, C | 1 |
| Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Szczylik, C; Zonierek, J | 1 |
| Agamah, E; Elit, L; Fleming, GF; Huo, D; Knost, JA; Morgan, RJ; Nimeiri, HS; Oza, AM; Vokes, EE; Wade, JL | 1 |
| Yen, Y; Zhou, W | 1 |
| Bhoori, S; Germini, A; Lampis, A; Mazzaferro, V; Pellegrinelli, A; Sposito, C; Toffanin, S | 1 |
| Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Guha-Thakurta, N; Korshunov, A; Pfister, S; Remke, M; Rokes, CA; Witt, O; Wolff, JE | 1 |
| Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH | 1 |
| Ikeda, K | 1 |
| Aucejo, F; Kim, R; Menon, N | 1 |
| Aucejo, F; Kim, R | 1 |
| Rowe, IA | 1 |
| Elit, L; Hirte, HW; Macalpine, K; Oza, AM; Schilder, RJ; Wang, L; Welch, SA; Wright, JJ | 1 |
| Bury, MJ; Floyd, JD; Gandara, DR; Gitlitz, BJ; Glisson, BS; Ho, C; Moon, J; Reimers, HJ; Schulz, TK; Sundaram, PK | 1 |
| Frederick, RT; Frenette, CT; Gish, RG | 1 |
| Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W | 1 |
| Aucejo, F; Byrne, M; Chang, YD; El-Gazzaz, G; Elson, P; Kim, R; Tan, A | 1 |
| Birrer, MJ; Bristow, RE; Calvert, V; Cohn, D; DeGeest, K; Farley, J; Lankes, HA; Matei, D; Mutch, D; Petricoin, EF; Sill, MW; Yamada, SD | 1 |
| FENG, FL; JIANG, XQ; LAU, WY; LIU, C; LUO, XJ; QIU, YH; Qiu, ZQ; RAN, RZ; TAN, WF; WANG, JH; WU, MC; YAN, PN; YI, B; YU, Y; ZHANG, BH | 1 |
| Hofmann, WP; Trojan, J; Waidmann, O; Zeuzem, S | 1 |
| Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ | 1 |
| Adnot-Desanlis, L; Bernard, P; Reguiaï, Z | 1 |
| Boeykens, E; Rutsaert, R; Stappaerts, I; Van Loo, S | 1 |
| Aglietta, M; Asaftei, SD; Casali, PG; D'Ambrosio, L; Dileo, P; Fagioli, F; Ferrari, S; Grignani, G; Mercuri, M; Palmerini, E; Picci, P; Pignochino, Y | 1 |
| Airoldi, A; Mancuso, A; Pinzello, G; Vigano, R | 1 |
| Dai, Z; Fan, J; Hu, J; Huang, XW; Qiu, SJ; Tan, CJ; Wang, Z; Zhou, J | 1 |
| Fukumoto, M; Ichida, T; Matsuda, Y | 1 |
| Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M | 1 |
| Li, XH; Liu, Y; Yang, DH; Zhong, KB; Zhou, J | 1 |
| Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X | 1 |
| Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C | 1 |
| Kudo, M | 1 |
| Düber, C; Galle, PR; Heise, M; Hoppe-Lotichius, M; Koch, S; Niederle, IM; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA | 1 |
| Cillo, U; Lombardi, G; Ramirez Morales, R; Vitale, A | 1 |
| Cohen, RA; Feusner, JH; Lo, L; Marsh, AM | 1 |
| He, H; Shen, Z; Wang, H; Wang, X; Wu, Y; Zhang, C; Zhao, J; Zhou, W; Zhu, Y | 1 |
| Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M | 1 |
| Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bertoni, M; Bozzi, E; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Neri, E; Parisi, G; Romano, A; Sacco, R; Sodini, E; Tumino, E | 1 |
| He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Wang, DP; Wang, GD; Wu, LW; Zhu, XF | 1 |
| Bondarde, S; Gradishar, WJ; Jain, M; Kaklamani, V; Lokanatha, D; Lokker, NA; Raina, V; Ro, SK; Sahoo, TP; Schwartzberg, L | 1 |
| Bechstein, WO; Trojan, J; Welker, MW; Zeuzem, S | 1 |
| Banzato, A; Bertorelle, R; Ciccarino, P; Della Puppa, A; Denaro, L; Farina, P; Fiduccia, P; Gardiman, MP; Lombardi, G; Polo, V; Zagonel, V; Zustovich, F | 1 |
| Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK | 1 |
| Fouzas, I; Klein, CG; Kykalos, S; Nowak, KW; Paul, A; Sotiropoulos, GC; Vernadakis, S | 1 |
| Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY | 1 |
| He, ZY; Hua, XD | 1 |
| Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
| Brendel, E; Christensen, O; Flashar, C; Grubert, M; Henning, BF; Hilger, RA; Kupsch, P; Ludwig, M; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R | 1 |
| Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C | 1 |
| Agulnik, M; Cheiken, R; Chen, EX; Chin, SF; Elser, C; Elting, J; Francis, P; McNabola, A; Petrenciuc, O; Pond, GR; Siu, LL; Wilkie, D; Winquist, E | 1 |
| Raspollini, MR | 1 |
| Avakian, R; Belldegrun, AS; Kabbinavar, FF; LaRochelle, JC; Pantuck, AJ; Patard, JJ; Riggs, SB; Shuch, B | 1 |
| Jonasch, E; Margulis, V; Matin, SF; Swanson, DA; Tamboli, P; Tannir, N; Wood, CG | 1 |
29 review(s) available for sorafenib and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies.
Topics: Antineoplastic Agents; Humans; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2022 |
Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma.
Topics: Calcineurin Inhibitors; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib; TOR Serine-Threonine Kinases | 2022 |
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Sorafenib | 2023 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
The efficacy of sorafenib in preventing hepatocellular carcinoma recurrence after resection: a systematic review and meta-analysis.
Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2020 |
Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review.
Topics: Allografts; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Drug Combinations; End Stage Liver Disease; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pharyngeal Neoplasms; Pharynx; Positron Emission Tomography Computed Tomography; Sorafenib; Tegafur; Treatment Outcome | 2020 |
Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib | 2020 |
Management of Recurrent HCC After Liver Transplantation.
Topics: Ablation Techniques; Allografts; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision-Making; Graft Rejection; Hepatectomy; Humans; Immunosuppressive Agents; Liver; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Patient Selection; Postoperative Period; Practice Guidelines as Topic; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Treatment Outcome | 2020 |
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Survival Analysis; Vascular Endothelial Growth Factor A | 2021 |
Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Prospective Studies; Sorafenib; Treatment Outcome | 2021 |
A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2021 |
Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Patient Selection; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib | 2017 |
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.
Topics: Antineoplastic Agents; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Glucocorticoids; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; IMP Dehydrogenase; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Hepatocellular carcinoma: clinical frontiers and perspectives.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Decision Support Techniques; Embolization, Therapeutic; Genome-Wide Association Study; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib | 2014 |
Sorafenib use in the transplant setting.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Treatment Outcome | 2014 |
Adjuvant therapy for hepatocellular carcinoma after curative treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Immunotherapy; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2015 |
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Interleukin-6; Liver Neoplasms; Membrane Glycoproteins; Microtubule-Associated Proteins; Neoplasm Recurrence, Local; Niacinamide; Nuclear Proteins; Oncogenes; Phenylurea Compounds; Prognosis; Receptors, Immunologic; Sirtuin 1; Sorafenib; Trans-Activators; Transcription Factors; Treatment Outcome; Triggering Receptor Expressed on Myeloid Cells-1 | 2015 |
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reoperation; Risk Factors; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Topics: Antineoplastic Agents; Female; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Publication Bias; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2015 |
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
[Oncology 2008].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2008 |
Current management of hepatocellular carcinoma.
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease Progression; Hepatectomy; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Liver Transplantation; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
[Current therapy for hepatocellular carcinoma].
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Embolization, Therapeutic; Hepatic Artery; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
Classic biphasic pulmonary blastoma: a case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Fatal Outcome; Humans; Intestinal Perforation; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pulmonary Blastoma; Pyridines; Sorafenib | 2011 |
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2011 |
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Trials as Topic; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Meta-Analysis as Topic; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Pyridines; Recombinant Proteins; Ribavirin; Sorafenib | 2011 |
Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
Topics: Animals; Carcinoma, Hepatocellular; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Blood Pressure; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2013 |
52 trial(s) available for sorafenib and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
Topics: Bronchiolitis Obliterans Syndrome; Disease Progression; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Sorafenib | 2023 |
Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Exons; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Nucleophosmin; Remission Induction; Sorafenib; Transplantation, Homologous; Young Adult | 2020 |
Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Interleukin-8; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sorafenib | 2020 |
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Sorafenib; Time Factors; Treatment Outcome | 2020 |
Hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study.
Topics: Administration, Topical; Bandages, Hydrocolloid; Clinical Trials, Phase III as Topic; Humans; Neoplasm Recurrence, Local; Ointments; Randomized Controlled Trials as Topic; Sorafenib | 2020 |
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Follow-Up Studies; Humans; Kidney Neoplasms; Metastasectomy; Neoplasm Recurrence, Local; Probability; Sorafenib | 2021 |
Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Prognosis; Sorafenib; Survival Rate; Vitamin K | 2021 |
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.
Topics: Adolescent; Adult; Antineoplastic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Sorafenib; Survival Rate; Young Adult | 2021 |
Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Phenylurea Compounds; Quinolines; Sorafenib | 2021 |
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Health Status Indicators; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate | 2017 |
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinolones; Sorafenib; Treatment Outcome | 2018 |
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Topics: Adult; Aged; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Serum Albumin; Sorafenib | 2017 |
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Sirolimus; Sorafenib; Survival Rate | 2018 |
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Furans; Humans; Ketones; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Salvage Therapy; Sorafenib; Survival Rate; Young Adult | 2018 |
Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Female; Hep G2 Cells; Humans; Liver Neoplasms; Liver Transplantation; Male; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Progression-Free Survival; Retrospective Studies; Sorafenib; Survival Analysis; Time Factors; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biopsy, Needle; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Predictive Value of Tests; Prognosis; Sorafenib; Survival Analysis; Tissue Embedding; Treatment Outcome | 2019 |
The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2019 |
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib; Survival Rate; Tandem Repeat Sequences; Young Adult | 2013 |
Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
Topics: Adolescent; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2013 |
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Proportional Hazards Models; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2014 |
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; gamma-Glutamyltransferase; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Double-Blind Method; Europe; Female; Hepatectomy; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; New Zealand; Niacinamide; North America; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; South America; Time Factors; Treatment Outcome; Young Adult | 2015 |
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Risk Factors; Sorafenib; Spain; Survival Rate; Treatment Outcome; Young Adult | 2016 |
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Hand-Foot Syndrome; Humans; Hypertension; Immunohistochemistry; Male; Middle Aged; Myoepithelioma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-ret; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Salivary Gland Neoplasms; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2016 |
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Sorafenib; Young Adult | 2009 |
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2009 |
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2010 |
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinosarcoma; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Uterine Neoplasms | 2010 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Cytochrome P-450 CYP3A; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib; Temozolomide | 2011 |
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyridines; Remission Induction; Salvage Therapy; Small Cell Lung Carcinoma; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate; Young Adult | 2011 |
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Osteosarcoma; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Failure; Treatment Outcome; Young Adult | 2012 |
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Diarrhea; Disease Progression; Drug Therapy, Combination; Everolimus; Female; Humans; Immunosuppressive Agents; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
[Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients].
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution; Treatment Outcome; Young Adult | 2011 |
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Topotecan | 2011 |
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Temozolomide; Vascular Endothelial Growth Factor A | 2013 |
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib | 2013 |
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Young Adult | 2012 |
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography | 2013 |
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution | 2013 |
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib | 2006 |
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2007 |
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Survival Rate | 2007 |
144 other study(ies) available for sorafenib and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma.
Topics: Denosumab; Humans; Hypercalcemia; Male; Middle Aged; Neoplasm Recurrence, Local; Parathyroid Hormone; Parathyroid Neoplasms; Sorafenib | 2022 |
Reducing Postoperative Recurrence of Early-Stage Hepatocellular Carcinoma by a Wound-Targeted Nanodrug.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Liver Neoplasms; Mice; Nanoparticles; Neoplasm Recurrence, Local; Sorafenib | 2022 |
Efficacy of Lipid Nanoparticle-Loaded Sorafenib Combined with Hepatic Artery Chemoembolization in the Treatment of Primary Hepatocellular Carcinoma Complicated with Microvascular Invasion.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatic Artery; Humans; Liposomes; Liver Neoplasms; Nanoparticles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2022 |
Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Propensity Score; Radiofrequency Ablation; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
The "SEED" Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain Tumors.
Topics: Brain Neoplasms; Child; Dasatinib; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Humans; Neoplasm Recurrence, Local; Patient Selection; Prospective Studies; Sorafenib; Young Adult | 2022 |
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Sorafenib | 2023 |
ABI2-mediated MEOX2/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Transformation, Neoplastic; Homeodomain Proteins; Humans; Kruppel-Like Factor 4; Liver Neoplasms; Nanog Homeobox Protein; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Sorafenib; Transcription Factors | 2022 |
LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F2 Transcription Factor; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Octamer Transcription Factor-1; Phenylurea Compounds; Quinolines; RNA, Long Noncoding; Sorafenib; Transcription Factors | 2022 |
Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma.
Topics: Antineoplastic Agents; Humans; Neoplasm Recurrence, Local; Paclitaxel; Phenylurea Compounds; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2022 |
A radiomics-based model can predict recurrence-free survival of hepatocellular carcinoma after curative ablation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib | 2023 |
Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib | 2023 |
SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.
Topics: Breast Neoplasms; Carcinoma, Hepatocellular; Fatty Acid Transport Proteins; Fatty Acids; Fatty Acids, Unsaturated; Female; Ferroptosis; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sorafenib; Tumor Microenvironment | 2023 |
Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Everolimus; Female; Humans; Male; Neoplasm Recurrence, Local; Osteosarcoma; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tyrosine Kinase Inhibitors; Young Adult | 2023 |
Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy.
Topics: Carcinoma, Hepatocellular; Glutamate-Ammonia Ligase; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Sorafenib | 2023 |
Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation.
Topics: Adult; Aged; Allografts; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Period; Retrospective Studies; Sorafenib; Survival Analysis; Time Factors; Time-to-Treatment; TOR Serine-Threonine Kinases; Treatment Outcome | 2020 |
Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Sunitinib | 2020 |
miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Feasibility Studies; Humans; Liver Neoplasms; Mice; MicroRNAs; Neoplasm Recurrence, Local; Phenotype; Sorafenib | 2020 |
Efficacy and Safety of Sorafenib After Liver Transplantation: Experience in Our Center.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Lineage; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Stem Cells; NF-E2-Related Factor 2; Prognosis; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
Topics: Aged; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exome Sequencing; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hepatectomy; Humans; Liver; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mutation; Neoplasm Recurrence, Local; Repressor Proteins; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Drugs, Chinese Herbal; Humans; Immunosuppression Therapy; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Recurrence, Local; Receptors, Tumor Necrosis Factor, Type I; Sorafenib; Tumor Cells, Cultured; Tumor Microenvironment; Tumor-Associated Macrophages; Xenograft Model Antitumor Assays | 2020 |
Letter to the Editor: Role of Sorafenib in Liver Transplantation Outcomes of Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria?
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Neoplasm Staging; Sorafenib | 2020 |
[A Case of Advanced Hepatocellular Carcinoma Successfully Treated with Liver Resection after Administration of Sorafenib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Sorafenib | 2020 |
Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aurora Kinase A; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Datasets as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Sorafenib; Up-Regulation; Young Adult | 2020 |
Hepatocellular carcinoma, novel therapies on the horizon.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib | 2021 |
[Effect of sorafenib and prophylactic TACE for prevention of postoperative relapse in patients with liver cancer combined with microvascular invasion].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib | 2020 |
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Mice, SCID; Mitochondria; Neoplasm Recurrence, Local; Protein Synthesis Inhibitors; Sorafenib; Tigecycline; Xenograft Model Antitumor Assays | 2020 |
Sorafenib for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2020 |
The Authors' Reply.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Sorafenib; TOR Serine-Threonine Kinases | 2020 |
Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
Topics: Animals; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; B7 Antigens; Carcinoma, Ovarian Epithelial; CD3 Complex; Cell Line, Tumor; Cell Proliferation; Datasets as Topic; Drug Synergism; Female; HEK293 Cells; Humans; Kaplan-Meier Estimate; Lymphocytes, Tumor-Infiltrating; Mice; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Sorafenib; T-Lymphocytes; Xenograft Model Antitumor Assays | 2020 |
ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Animals; Antigens, CD; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factors; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sialyltransferases; Sorafenib | 2021 |
Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoconjugates; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib | 2021 |
[A Case in Which Multiple Post-Operatively Recurring Hepatocellular Carcinomas Showed a Positive Response to Sorafenib-Hepatic Arterial Infusion Chemotherapy (HAIC)Sequential Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2021 |
High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients.
Topics: Carcinoma, Hepatocellular; Everolimus; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib | 2021 |
The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Acetylation-induced PCK isoenzyme transition promotes metabolic adaption of liver cancer to systemic therapy.
Topics: Acetylation; Adaptation, Physiological; Cell Line; Cell Line, Tumor; Cytoplasm; HEK293 Cells; Hep G2 Cells; Histone Acetyltransferases; Humans; Isoenzymes; Liver; Liver Neoplasms; Neoplasm Recurrence, Local; Phenylurea Compounds; Phosphoenolpyruvate Carboxykinase (ATP); Progression-Free Survival; Quinolines; Sorafenib | 2021 |
Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Sorafenib | 2021 |
Complete Response to Sorafenib in Locally Recurrent Unresectable Aggressive Fibromatosis.
Topics: Fibromatosis, Aggressive; Humans; Neoplasm Recurrence, Local; Sorafenib | 2021 |
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Drug Approval; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Treatment Outcome | 2022 |
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Registries; Sorafenib | 2017 |
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome | 2017 |
Management of hepatocellular carcinoma recurrence after liver transplant is far from perfect.
Topics: Adult; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Registries; Sorafenib | 2018 |
Desmoid Tumors and Celecoxib with Sorafenib.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2017 |
Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor: Analysis of a preliminary experience on 15 consecutive cases.
Topics: Adult; Aged; Antineoplastic Agents; Blood Vessel Prosthesis; End Stage Liver Disease; Female; Hepatectomy; Hepatic Veins; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Complications; Sorafenib; Treatment Outcome; Young Adult | 2017 |
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation.
Topics: Administration, Metronomic; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hematologic Neoplasms; Hepacivirus; Hepatectomy; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Patient Selection; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Serologic Tests; Sorafenib; Survival Rate; Young Adult | 2017 |
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Combined Modality Therapy; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gain of Function Mutation; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Domains; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Segmental Duplications, Genomic; Sorafenib; Survival Rate; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2018 |
No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Survival Rate | 2018 |
[Insight and judgment on recurrence of hepatocellular carcinoma after liver transplantation].
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Humans; Judgment; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2018 |
Locoregional versus systemic therapy - robust positive data remain elusive.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib | 2018 |
Treatment of platinum refractory or resistant ovarian cancer.
Topics: Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sorafenib; Topotecan | 2018 |
Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Follow-Up Studies; Guideline Adherence; Humans; Incidence; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Postoperative Period; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2019 |
Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib; Tacrolimus; TOR Serine-Threonine Kinases | 2018 |
Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2018 |
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Republic of Korea; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy: A multicenter retrospective study.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Retrospective Studies; Risk Factors; Sorafenib | 2019 |
Sorafenib improves survival of
Topics: Adult; Aged; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Registries; Remission Induction; Retrospective Studies; Salvage Therapy; Sorafenib; Transplantation, Homologous; Treatment Outcome; Young Adult | 2019 |
[Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2019 |
Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver; Liver Neoplasms; Male; Microvessels; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib; Treatment Outcome | 2019 |
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Adenoid Cystic; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Recurrence, Local; Pericardium; Pleural Neoplasms; Progression-Free Survival; Retrospective Studies; Salivary Gland Neoplasms; Sorafenib | 2020 |
Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Tumor Burden | 2020 |
CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; Connective Tissue Growth Factor; Down-Regulation; Drug Resistance, Neoplasm; Feedback; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxaliplatin; Protein Kinase Inhibitors; RNA, Messenger; Sorafenib; Up-Regulation | 2019 |
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Sorafenib; Young Adult | 2019 |
Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Humans; Mice; Neoplasm Recurrence, Local; Osteosarcoma; Piperazines; Pyridines; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
Topics: Animals; Apoptosis; Disease Models, Animal; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; Liver Transplantation; Male; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Inbred ACI; Rats, Inbred Lew; Sorafenib; Tissue Array Analysis | 2013 |
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; In Vitro Techniques; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Smad7 Protein; Sorafenib; Transforming Growth Factor beta; Up-Regulation | 2013 |
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence.
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Cyclin G1; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; SOXB1 Transcription Factors; TOR Serine-Threonine Kinases | 2013 |
Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
[Complete remission by sorafenib for local reccurence of renal cell carcinoma with a tempraly elevation of C-reactive protein: a case report].
Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib | 2013 |
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Complications; Retrospective Studies; Sirolimus; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Clofarabine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Young Adult | 2014 |
Multi-kinase inhibition in ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2014 |
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Topics: Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Radiopharmaceuticals; Radiotherapy, Adjuvant; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pleural Effusion, Malignant; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome | 2014 |
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Interactions; Everolimus; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2014 |
Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Palliative Care; Phenylurea Compounds; Pilot Projects; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2014 |
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression; Head and Neck Neoplasms; Humans; Hyperplasia; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2015 |
Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2015 |
Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.
Topics: Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Care; Retrospective Studies; Sorafenib; Survival Analysis | 2014 |
A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Viral Load | 2015 |
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Niacinamide; Osteosarcoma; Phenylurea Compounds; Pneumothorax; Sarcoma, Ewing; Sarcoma, Synovial; Sorafenib; Wilms Tumor; Young Adult | 2015 |
Sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a report of four cases.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Tomography, X-Ray Computed | 2015 |
NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cyclosporine; Drug Resistance, Neoplasm; Flow Cytometry; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; NFATC Transcription Factors; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sorafenib; Survival Rate; Tandem Repeat Sequences; Tumor Cells, Cultured | 2015 |
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Ascorbic Acid; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer.
Topics: Aged; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Thyroidectomy | 2015 |
Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2015 |
Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combined Modality Therapy; Follow-Up Studies; Graft Survival; Humans; Liver Neoplasms; Liver Transplantation; Lymphocytes; Multivariate Analysis; Neoplasm Recurrence, Local; Neutrophils; Niacinamide; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Survival Rate | 2015 |
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Remission Induction; Republic of Korea; Retrospective Studies; Sorafenib | 2015 |
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Sorafenib; Thyroid Neoplasms | 2016 |
Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment.
Topics: Aged; Blood Pressure; Brain; Carcinoma, Renal Cell; Female; Humans; Hypertension; Immunosuppressive Agents; Kidney Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Neoplasm Recurrence, Local; Posterior Leukoencephalopathy Syndrome; Sorafenib; Thrombosis; Vascular Endothelial Growth Factor A | 2018 |
Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Posterior Leukoencephalopathy Syndrome; Salvage Therapy; Sorafenib | 2016 |
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML.
Topics: Alopecia; Antineoplastic Agents; Child, Preschool; Female; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Tissue Donors | 2016 |
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Topics: Adult; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hepatitis B; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Proto-Oncogene Proteins c-raf; Recurrence; Retrospective Studies; Sorafenib | 2016 |
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Sorafenib; Treatment Outcome | 2016 |
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sirolimus; Sorafenib | 2016 |
[Prediction and preventive strategies for recurrence after surgery for hepatocellular carcinoma].
Topics: Biopsy; Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Immunotherapy; Interferons; Liver Neoplasms; MicroRNAs; Neoplasm Recurrence, Local; Niacinamide; Osteopontin; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2016 |
Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma.
Topics: Antineoplastic Agents; Chordoma; Graves Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2016 |
Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; China; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Liver Transplantation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Surveys; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Quality of Life; Salvage Therapy; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment | 2009 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes | 2009 |
[Prospect of hepatocellular carcinoma in 2008].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diagnosis, Differential; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Polymerase Chain Reaction; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2009 |
Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Protocols; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2009 |
Hepatocellular carcinoma: the search for innovative adjuvant therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Neoplasm Seeding; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib | 2009 |
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; beta Catenin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; DNA Mutational Analysis; Everolimus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Point Mutation; Precision Medicine; Pyridines; Ribavirin; Sirolimus; Sorafenib | 2010 |
Sorafenib plus valproic acid for infant spinal glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Extracellular Signal-Regulated MAP Kinases; Female; Glioblastoma; Humans; Immunohistochemistry; Infant; MAP Kinase Kinase Kinases; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy; raf Kinases; Sorafenib; Spinal Cord Neoplasms; Valproic Acid | 2010 |
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Female; Hematologic Diseases; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2010 |
Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib | 2011 |
Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Diagnostic Imaging; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sirolimus; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Fatal Outcome; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2011 |
Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Administration Schedule; Feasibility Studies; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2010 |
mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Everolimus; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2011 |
Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transplantation, Heterologous; Treatment Outcome | 2011 |
[Squamous cell carcinoma in a patient receiving sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cooperative Behavior; Follow-Up Studies; Humans; Interdisciplinary Communication; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Diseases | 2011 |
An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Chemotherapy, Adjuvant; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Tacrolimus | 2012 |
Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
Topics: alpha-Fetoproteins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Child, Preschool; Hepatoblastoma; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sorafenib | 2012 |
Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tomography, X-Ray Computed | 2012 |
[Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Liver Transplantation; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2012 |
Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2012 |
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Iodized Oil; Liver Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate | 2012 |
Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2007 |
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |